At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 4,008 enrolled
Drug / intervention
Lorcaserin 10 mg once daily (QD) +2 moredrug
Likely dose
Lorcaserin 10 mg once daily (QD)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 52-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of Lorcaserin Hydrochloride in Overweight and Obese Patients
In Brief
A Phase 3 clinical trial evaluating Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID), and 1 other intervention for Obesity. Completed, enrolled 4,008 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedJan 2008
Primary CompletionJul 2009
Study CompletionAug 2009
TodayJul 2026
First PostedJan 29, 2008
Enrollment StartJan 1, 2008
Primary CompletionJul 1, 2009
Study CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 18.4 years ago
Interventions
Lorcaserin 10 mg once daily (QD)drug
Lorcaserin 10 mg tablet each morning and placebo tablet each evening for a duration of 52 weeks.
Lorcaserin 10 mg twice a day (BID)drug
Lorcaserin 10 mg tablet each morning and evening for a duration of 52 weeks.
Matching Placebodrug
Matching placebo tablet each morning and evening for a duration of 52 weeks.